Company intelligence / Profile preview
Esperion Therapeutics
Ann Arbor, Michigan, United Statesesperion.com ↗
- Ownership
- Public · ESPR
- Employees
- ~200
- Development stage
- Other
01
Overview
Esperion Therapeutics has two FDA- and EMA-approved oral therapies for lowering LDL-cholesterol—bempedoic acid (Nexletol/Nilemdo) and its fixed-dose combination with ezetimibe (Nexlizet/Nustendi)—with over 14,000 patients enrolled in outcomes trials, and is advancing pediatric and next-generation ATP citrate lyase inhibitor programs.[1][2]
- Therapeutic areas
- Cardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Daiichi Sankyo
Beyond the preview
Go deeper on Esperion Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Esperion Therapeutics.